TrialAesthetic surgery journal2025

Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial.

Michael H Gold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.